Drug Profile
GSK 3036656
Alternative Names: GSK 3036656; GSK656Latest Information Update: 14 Apr 2024
Price :
$50
*
At a glance
- Originator Anacor Pharmaceuticals
- Developer GSK
- Class Antibacterials; Antituberculars; Organic boron compounds; Small molecules
- Mechanism of Action Leucyl-tRNA synthetase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Tuberculosis
Most Recent Events
- 05 Apr 2024 GlaxoSmithKline plans a phase I trial for Tuberculosis (Prevention) in Spain (PO) (NCT06354257)
- 11 Oct 2023 Pharmacodynamic data from preclinical study in Tuberculosis presented at the IDWeek (IDW-2023)
- 14 Nov 2022 Antimicrobial and adverse event data from a phase II trial in Tuberculosis released by GlaxoSmithKline